NCT04565197 is a EARLY_PHASE1 clinical trial of convalescent plasma in SARS-CoV Infection, sponsored by Lahore General Hospital.

Who is sponsoring NCT04565197?

NCT04565197 is sponsored by Lahore General Hospital.

What drugs are being tested in NCT04565197?

Interventions in NCT04565197: convalescent plasma.

What condition does NCT04565197 study?

NCT04565197 studies SARS-CoV Infection.

Is NCT04565197 still recruiting?

NCT04565197 is currently status unknown. Last updated 8 December 2020.

Last reviewed 2020-12-08 · How we verify

NCT04565197

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Convalescent Plasma Therapy for COVID-19 Patients

Status unknown EARLY_PHASE1 Last updated 8 December 2020

What this trial tests

EARLY_PHASE1 trial testing convalescent plasma in SARS-CoV Infection in 20 participants. Status unknown.

Timeline

1 May 2020

Primary endpoint
30 December 2020

30 December 2020

Quick facts

Lead sponsor	Lahore General Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 May 2020
Primary completion	30 December 2020
Estimated completion	30 December 2020
Sites	1 location across Pakistan

Drugs / interventions tested

convalescent plasma — full drug profile →

Conditions studied

SARS-CoV Infection — all drugs for SARS-CoV Infection →

Sponsor

Lahore General Hospital

Who can join

Adults 15 to 80, any sex, with SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Passive immunization involves the administration of antibodies against a given agent to a susceptible individual for the purpose of preventing or treating an infectious disease due to that agent. A general principle of passive antibody therapy is that it is more effective when used for prophylaxis than for treatment of disease. When used for therapy, antibody is most effective when administered shortly after the onset of symptoms

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6

Verify or expand the search:

Other trials of convalescent plasma

Trials testing the same drug.

NCT04388410 — Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19 · Phase 2, PHASE3 · unknown
NCT04415086 — Treatment of Patients With COVID-19 With Convalescent Plasma · Phase 2 · completed
NCT04616976 — COVID-19 With Convalescent Plasma · completed

Other recruiting trials for SARS-CoV Infection

Currently open trials in the same condition.

NCT05886816 — Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 · Phase 2 · recruiting
NCT04802408 — SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial · Phase 2, PHASE3 · active not recruiting
NCT04815096 — Imaging Immune Activation in COVID-19 · Phase 2 · recruiting
NCT04747522 — Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19) · active not recruiting
NCT04579471 — Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study · recruiting

Other Lahore General Hospital trials

Trials by the same sponsor.

NCT07470359 — Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and With · Phase 2 · recruiting
NCT07261306 — Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis · EARLY_PHASE1 · recruiting
NCT07112898 — Effect of Platelet-Rich Plasma on Graft Uptake and Postoperative Outcomes in Full-Thickness Skin Grafting of Face and Ne · NA · enrolling by invitation
NCT07478874 — Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic · NA · completed
NCT07460908 — Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04565197 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lahore General Hospital
Last refreshed: 8 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04565197.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing